Assessment of the Initial Efficacy and Safety of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis

NCT05927428 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Neurotrophic Keratitis

Interventions

DRUG: BRM424 Ophthalmic Solution - Dose1
DRUG: BRM424 Ophthalmic Solution - Dose2

Sponsor

BRIM Biotechnology Inc.